NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/16/2025
Back to search
Official data from USPTO
ZYAMTIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
12
Latest update
12/17/2025
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
05/08/2025
Registration date
12/16/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/16/2025
Last transaction
12/17/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
26
Owner location
Amsterdam, NL
Examiner
WOODS,TRAVIS ROBERT
Law office
O80
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
uniQure biopharma B.V.
Representatives
JULIANNE ABELMAN ABELMAN LAW PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapygene diagnosisgene testing; pharmaceutical preparationsvaccines for use in gene therapy; pharmaceutical preparations for the treatment of Dravet's diseaseAlzheimer's diseaseALSHuntington's diseaseFragile X syndromeParkinson's diseaseA1AT deficiencyepilepsytemporal lobe epilepsyfocal cortical dysplasiaFabry diseasemultiple system atrophyspinocerebellar ataxia and dyslipidemia; gene therapy and prophylaxis productsgene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disorderscancerinflammatory and auto-immune diseasesvascular disorderssingle gene disorders
Publications
History of USPTO decisions and trademark events.
12 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/16/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/28/2025
PUBO
PUBLISHED FOR OPPOSITION
10/28/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/22/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/24/2025
DOCK
ASSIGNED TO EXAMINER
09/24/2025
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
06/20/2025
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
06/20/2025
MAFR
APPLICATION FILING RECEIPT MAILED
05/08/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/08/2025
NWAP
NEW APPLICATION ENTERED
05/08/2025
Continuous trademark protection
Get notified about every new filing that threatens ZYAMTIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.